

For immediate release

4 February 2013



Accentus Medical Strengthens Board of Directors to Support Growth Drive

Oxford, 4 February 2013 ... Accentus Medical, a global leader in silver-based anti-microbial implant surfaces, is pleased to announce the appointment of Brian Howlett and Laurie Rostron to its board of directors.

Brian Howlett is a successful international business leader with more than 20 years' experience of building and managing medical device and diagnostic businesses. As CEO of AIM-quoted Lombard Medical Technologies plc from 2005 to 2010, he took the company from the development stage to product sales. He also raised a total of £49 million in equity funding in challenging financial markets. From 1999 to 2005, Brian was UK Country Leader at Boston Scientific Corporation, where he was responsible for launching a number of new medical devices into the UK market. He is now utilising this experience in a portfolio of non-executive directorships and business consultancy roles.

Brian said "Accentus Medical has demonstrated considerable early stage success in commercialising its innovative surface technologies, notably the breakthrough Agluna® anti-microbial surface technology, providing a solution to the multi-\$bn unmet market need of implant related infection. This success has been achieved through the vision, commitment and entrepreneurial drive of the current management team over the past several years. I am delighted to have the opportunity to join the board at this exciting stage of the company's development. I look forward to supporting the management team on the next phase of its journey, as we seek to achieve broader commercialisation of Agluna®, and our other leading edge implant surface technologies, across the medical device market."

Laurie Rostron is an experienced Non-Executive Director of SME's operating in the healthcare / medical device industry, and is an advisor to a number of venture capital partnerships. He has a track record of successful investments in the healthcare industry, particularly with start-up and early stage companies commercialising leading edge technologies in high growth international markets. He was previously a partner at Alta Berkeley Associates, focused on healthcare investments.

Laurie said "Having worked as business advisor to Accentus Medical for a number of years, I welcome the opportunity to join the company's board of directors. Under the current management team, the company has achieved a great deal, delivering consistent year-on-year growth in revenue streams with an increasing portfolio of international medical device customers. This team now has an ambitious growth plan to expand its customer base, and to develop its core Acusure® and Agluna® technology platforms so as to unlock further global market potential for these value-enhancing products."

Philip Agg, Chief Executive Officer said: *"I am delighted to welcome Brian and Laurie to the board of directors. I and the wider management team look forward to benefitting from their wisdom, insight and experience of working with high growth companies within the global medical device industry."*

-ends-

For further information, please contact:

Lynne Trowbridge, Tim Watson

Accentus Medical

T: +44 (0)20 7866 7861

Email: AccentusMedical@collegehill.com

About Accentus Medical

Accentus Medical is a global leader in delivery of innovative, silver-based anti-microbial surface treatments and biocompatible coatings on implantable medical devices. The company combines a long history of expertise in surface technologies, with dedicated research and development of new technologies for the medical device industry. Based at the historic Harwell Oxford campus, Accentus Medical has provided expertise in surface technologies to the orthopaedic device industry since the 1970s, serving major orthopaedic and medical device manufacturers worldwide.

The company has two principal technology platforms: Agluna[®] silver anti-microbial surface treatment for prevention and control of post-operative infection, and Acusure[®] plasma spray coating for improving biocompatibility and durability of implants. These technologies are supplied to customers at Accentus Medical's ISO13485:2003 and ISO9001:2008 accredited facility. Accentus Medical is also very well known for the medical device testing programmes offered by its in-house test laboratories. Manufacturers have been utilising test results provided by the company for many years as part of device homologation files all over the world.

For further information, please visit: www.accentus-medical.com